USPTO serial 98326058
FERTIN PHARMA
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- BHANOT, KAPIL KUMAR
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with FERTIN PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $449*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Tamar Niv Bessinger
Tamar Niv Bessinger Fross Zelnick Lehrman & Zissu, P.C.151 West 42nd St., 17th FloorNew York, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, smoking cessation preparations, analgesic preparations, sleep aid- preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; pharmaceutical preparations, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders in chewable form, in gum form, in lozenge form, and in pouch powder form; aerosolized and inhaled therapeutics and pharmaceuticals, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti- pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; pharmaceutical preparations for inhalation, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; drug delivery agents in the form of fast liquefiable tablets, compressed gum, extruded gum, lozenges, pouch powder, dissolvable films, coatings for tablets, and transdermal patches that facilitate the delivery of pharmaceutical preparations, namely, smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; vitamins and dietary supplements; dietetic foodstuffs adapted for medical purposes; nicotine gum for use as an aid to stop smoking; medicated chewing gum as a drug delivery agent to facilitate the delivery of pharmaceutical preparations; dietetic preparations for medical use; herbal extracts for medical purposes; herbal teas for medicinal purposes | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals and nutraceuticals; consultancy regarding the custom manufacture of pharmaceuticals and nutraceuticals; custom manufacture of pharmaceuticals, namely, formulation of pharmaceutical preparations for treatment of a wide variety of conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; custom manufacture of pharmaceuticals, namely, formulation of inhaled therapeutics; custom manufacture of pharmaceuticals, namely, formulation of pharmaceuticals and well-being products for oral and intra-oral delivery systems; research, and development of pharmaceuticals and well-being products for oral and intra-oral delivery systems; custom manufacture of pharmaceuticals, namely, formulation of pharmaceuticals for smoking cessation; provision of advice, information and consultancy in relation to the aforesaid services | ACTIVE | — |
| 042 | Scientific, medical and technological services and research and design relating thereto namely, research and development of technology in the field of smoking cessation preparations, analgesic preparations, sleep aid-preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; industrial analysis and industrial research services in the field of pharmaceutical research and development services; research, and development of pharmaceutical preparations for treatment of a wide variety of conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; research and development of inhaled therapeutics; research, and development of pharmaceuticals and well-being products for oral and intra-oral delivery systems; research and development of pharmaceuticals for smoking cessation; provision of advice, information and consultancy in relation to the aforesaid service | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 17, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 15, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 15, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 15, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 26, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 25, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 25, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 25, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 4, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 14, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 13, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 13, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 26, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 15, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 15, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 25, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 5, 2024 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Sep 4, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 4, 2024 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Aug 21, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 21, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 21, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 24, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 24, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 24, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 23, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 3, 2024 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Apr 2, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 2, 2024 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Dec 21, 2023 | NWAP | NEW APPLICATION ENTERED | — |